Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
MindMaze Therapeutics Holding had a gross margin of 92.06% for the quarter that ended in Dec. 2025 => Durable competitive advantage
MindMaze Therapeutics Holding Gross Profit Related Terms
MindMaze Therapeutics Holding Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding Gross Profit Chart
MindMaze Therapeutics Holding Annual Data
Trend
Dec24
Dec25
Gross Profit
0.00
0.59
MindMaze Therapeutics Holding Semi-Annual Data
Dec24
Dec25
Gross Profit
0.00
0.59
XSWX:MMTX vs VRTX, REGN, ALNY: Gross Profit Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Gross Profit distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's Gross Profit falls into.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.59 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
MindMaze Therapeutics Holding (XSWX:MMTX) has a Gross Profit of CHF0.59 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Gross Profit too high?
MindMaze Therapeutics Holding's current Gross Profit is CHF0.59 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Gross Profit compare to VRTX and REGN?
MindMaze Therapeutics Holding's Gross Profit of CHF0.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Gross Profit is CHF0.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Gross Profit of CHF0.59 Mil. The current Gross Profit is CHF0.59 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Gross Profit is CHF0.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score
Get the complete analysis for XSWX:MMTX
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MMTX has been successfully added to your 
